The startup, which has already raised more than half a billion dollars, released Phase 2 results that could position its drug ...
GlobalData has named heart failure as the next disease to feel the sales-boosting power of GLP-1 drugs. The analysts expect ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback